New therapies for treating Down syndrome require quality of life measurement

@article{Goodman2013NewTF,
  title={New therapies for treating Down syndrome require quality of life measurement},
  author={M. Goodman and D. Brixner},
  journal={American Journal of Medical Genetics Part A},
  year={2013},
  volume={161}
}
  • M. Goodman, D. Brixner
  • Published 2013
  • Medicine
  • American Journal of Medical Genetics Part A
    • Down syndrome (DS) is the most common genetic cause of cognitive deficits. Using mouse models and therapies for Alzheimer disease, researchers are exploring therapies that may improve cognitive function in people with DS. These developments shift the health economic paradigm of understanding DS from determining the appropriate screening tool to the effect of therapy on quality of life in those with DS. To date, there are no validated quality of life instruments for DS. Research should begin to… CONTINUE READING
    View on Wiley
    ncbi.nlm.nih.gov
    7 Citations
    Highly Influencial Citations
    1
    Background Citations
    4

    Topics from this paper

    Explore Further: Topics Discussed in This Paper

    7 Citations
    Citation Type

    Citation Type

    Down Syndrome and Quality of Life: A Case Report
    • 1
    • PDF
    Cost-effectiveness analysis for triple markers serum screening for Down's syndrome in Thai setting
    • 2
    Vision problems in Down syndrome adults do not hamper communication, daily living skills and socialisation
    • 5
    • PDF
    Health-related Quality of Life (HR-QOL) and Chronic Health Conditions in Survivors of Childhood Acute Myeloid Leukemia (AML) with Down Syndrome (DS): A Report From the Children’s Oncology Group
    • 9
    Quality of health care according to people with Down syndrome, their parents and support staff—A qualitative exploration
    • 4
    • Highly Influenced
    • PDF
    Adapting a Measure of Quality of Life to Children with Down Syndrome for the Development of Evidence-based Interventions
    • 3
    • PDF
    Gajra Raja Medical College, Madhya Pradesh, India
    • A. Alcaraz, Ziad Jamil Al-Sabe, +18 authors Yaneth Mora Márquez
    • 2015

    References

    SHOWING 1-10 OF 37 REFERENCES
    Down syndrome and Alzheimer disease: response to donepezil.
    • 87
    • PDF
    Donepezil Significantly Improves Abilities in Daily Lives of Female down Syndrome Patients with Severe Cognitive Impairment: A 24-Week Randomized, Double-Blind, Placebo-Controlled Trial
    • 42
    Donepezil for the treatment of language deficits in adults with Down syndrome: A preliminary 24‐week open trial
    • 50
    Safety and efficacy of rivastigmine in adolescents with Down syndrome: a preliminary 20-week, open-label study.
    • 37
    Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome
    • 439
    Donepezil for treatment of cognitive dysfunction in children with Down syndrome aged 10–17
    • 59
    Effects of donepezil on cognitive functioning in Down syndrome.
    • 48
    Dramatic Improvement in down Syndrome—Associated Cognitive Impairment with Donepezil
    • 16
    Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial
    • 133
    Preliminary study of the safety and efficacy of donepezil hydrochloride in children with Down syndrome: A clinical report series
    • 40